Document is current
Any future updates will be listed below
-
Authors
Hinchcliffe, Justyna K.
Kamenish, Katie
Bartlett, Julia
Arban, Roberto
Hengerer, Bastian https://orcid.org/0000-0002-7811-9795
Robinson, Emma S. J. https://orcid.org/0000-0002-1299-6541
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N015762/1)
- License Information
-
More Information
Article History
Received: 11 September 2025
Revised: 16 April 2026
Accepted: 19 May 2026
First Online: 29 May 2026
Competing interests
: ESJR has obtained research funding from Boehringer Ingelheim, Compass Pathways plc, Eli Lilly, IRLab Therapeutics, MSD, Pfizer and Small Pharma. ESJR has been paid as a consultant or invited speaker by Compass Pathways, Pangea Botanicals and Charles River. BH and RA are currently employed by Boehringer Ingelheim GmbH & Co. JKH, KK and JB declare no conflicts of interest.
